Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Advanced Solid Tumor
Interventions: RP3, Nivolumab; Biological
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Iowa City, Iowa • Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Malignant Glioma
Interventions: lerapolturev, Lomustine; Biological · Drug
Lead sponsor: Istari Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more

Conditions: Renal Insufficiency, Healthy
Interventions: Canagliflozin (JNJ-28431754); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Chemotherapy-Induced Nausea and Vomiting
Interventions: Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: Up to 16 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: Maharishi Ayurveda Lifestyle Program; Behavioral
Lead sponsor: Maharishi International University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Asheville, North Carolina

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: erlotinib, sunitinib, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 18
States / cities: Birmingham, Alabama • Mobile, Alabama • Antioch, California + 13 more

Conditions: Multiple Myeloma
Interventions: Vermurafenib; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Developmental Language Disorder, Explicit Intervention, Grammatical Language
Interventions: Implicit-only, Explicit-added; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 5 Years to 9 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetic Neuropathy, Distal Symmetric Polyneuropathy (Manifestation)
Interventions: Intraneural Facilitation® Therapy (INF® Therapy), INF® Therapy; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Treatment Resistant Depression
Interventions: Olanzapine and Fluoxetine combination (OFC), Fluoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 36
States / cities: Pasadena, California • Sherman Oaks, California • Wildomar, California + 33 more

Conditions: Healthy
Interventions: TG-0054; Drug
Lead sponsor: GPCR Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Overweight, Eating Disorders
Interventions: Emotion regulation group therapy, Orlistat/alli program; Behavioral · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions: Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells; Drug
Lead sponsor: David Wald; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Blood Loss, Surgical
Interventions: rThrombin, 1000 IU/mL; Biological
Lead sponsor: ZymoGenetics; Industry
Eligibility: Up to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Substance-Related Disorders, Alcohol-Related Disorders
Interventions: The Women's Recovery Group, Group Drug Counseling; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Belmont, Massachusetts • Fall River, Massachusetts

Conditions: Focus: Effect of Muscle Activation on CMAP in Normal Humans
Interventions: Hypothenar muscle activation--maximum, voluntary, isometric, Thenar muscle activation--maximum, voluntary, isometric, EDB muscle activation--maximum, voluntary, isometric, Relaxation of muscle; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: AL Amyloidosis
Interventions: 124I-labeled monoclonal antibody Mu 11-1F4; Biological
Lead sponsor: University of Tennessee; Other
Eligibility: 21 Years to 90 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Dermatomyositis, Adult Type
Interventions: Apremilast 30mg; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Cytomegalovirus, Adenovirus
Interventions: VST infusion, CliniMACS; Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Head Injury
Interventions: Place HOB in alternate positions from 0-50 degrees.; Procedure
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Azilsartan medoxomil (TAK-491); Drug
Lead sponsor: Takeda; Industry
Eligibility: 1 Year to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Little Rock, Arkansas • Atlanta, Georgia • Louisville, Kentucky + 1 more

Conditions: Brain Tumor
Interventions: [18F]FLT, [18F]Fluciclovine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: trebananib, cytarabine, laboratory biomarker analysis, pharmacological study; Biological · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Buffalo, New York • Rochester, New York

Conditions: Advanced Solid Tumor
Interventions: LDE225, Wafarin, Bupropion; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 13
States / cities: Duarte, California • Kansas City, Kansas • Boston, Massachusetts + 9 more

Search by objective public record fields.

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Lerapolturev in Recurrent Malignant Glioma

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

Ayurveda Diet & Lifestyle Protocol for Type 2 Diabetes: A Feasibility Study

A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

Evaluation of an Explicit Approach

Effect of Gluten-Free Dietary Education and Intraneural Facilitation® Therapy on Quality of Life in People With Diabetic Neuropathy

A Study in Relapse Prevention of Treatment-Resistant Depression

Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers

Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants

Women's Recovery Group (WRG) Study - A Randomized Controlled Stage II Trial

The Effect of Prior Muscle Activation on the Compound Muscle Action Potential (CMAP)

Radioimmunoimaging of AL Amyloidosis

Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

Effects of Head Elevation on Intracranial Pressure in Children

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients